Published in Cancer Treat Rep on October 01, 1977
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood (2011) 1.02
Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemother Pharmacol (2007) 0.96
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol (2015) 0.93
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemother Pharmacol (2010) 0.89
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget (2012) 0.89
Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res (1968) 2.67
High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (1977) 2.07
Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth (2012) 2.05
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol (1999) 1.87
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst (1992) 1.79
Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest (1990) 1.57
Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Invest (1993) 1.50
Isolation and purification of L-methionine-alpha-deamino-gamma-mercaptomethane-lyase (L-methioninase) from Clostridium sporogenes. Cancer Res (1973) 1.50
Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest (2000) 1.49
Comparison of different treatment strategies for diffuse large-cell lymphomas: a decision analysis. Med Decis Making (1991) 1.38
Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer. Cancer Invest (2000) 1.37
Toxicity of E. coli L-asparaginase in man. Cancer (1970) 1.36
Cancer chemotherapeutic agents. CA Cancer J Clin (1977) 1.15
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer (1974) 1.15
Methionine requirement and replacement by homocysteine in tissue cultures of selected rodent and human malignant and normal cells. Cancer Res (1978) 1.10
Nephrotoxicity of cis-dichlorodiammineplatinum(II). Cancer Treat Rep (1980) 1.10
Adriamycin--an antitumor antibiotic in the treatment of neoplastic diseases. Cancer (1973) 1.10
Quinacrine (Atabrine) in the treatment of neoplastic effusions. Ann Intern Med (1967) 1.07
Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med (1972) 1.07
Use of allopurinol in preventing hyperuricemia in leukemia and lymphoma. Cancer (1966) 1.06
Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature. Cancer (1977) 1.03
Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease. Cancer Res (1982) 1.01
Biological effects of enzymatic deprivation of L-methionine in cell culture and an experimental tumor. Cancer Res (1973) 1.00
A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. Breast Cancer Res Treat (1982) 1.00
Urinary metabolites in congenital hyperuricosuria. Science (1967) 0.98
Effects of hydroxyurea on polyoma virus replication. Cancer Res (1968) 0.97
Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol (1994) 0.96
Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer (1979) 0.95
Induction of interferon in human subjects by poly I:C. Proc Soc Exp Biol Med (1971) 0.94
Distribution pattern and enzymic hypermethylation of inverted repetitive DNA sequences in P815 mastocytoma cells. Biochim Biophys Acta (1979) 0.93
Clinical experience with L-asparaginase. Recent Results Cancer Res (1970) 0.93
Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep (1979) 0.93
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol (1999) 0.92
Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis. Cancer Chemother Pharmacol (2001) 0.92
Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics (1968) 0.91
Effect of nutritional and enzymatic methionine deprivation upon human normal and malignant cells in tissue culture. Cancer Res (1980) 0.91
Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology (1975) 0.90
Tumor therapy by deprivation of L-methionine: rationale and results. Cancer Treat Rep (1979) 0.90
Kinetics of metoprine, a lipid-soluble antifolate. Br J Clin Pharmacol (1981) 0.90
Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer (1980) 0.89
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother (1992) 0.89
Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol (1992) 0.89
Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol (1993) 0.89
Purification of deoxycytidine kinases from two P815 murine neoplasms and their separation from deoxyguanosine kinase. Arch Biochem Biophys (1976) 0.89
Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep (1973) 0.89
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol (1993) 0.88
In vitro metabolism of 1-beta-D-arabinofuranosylcytosine and 1-beta-2'-fluoroarabino-5-iodocytosine in normal and herpes simplex type 1 virus-infected cells. Biochem Pharmacol (1982) 0.87
Study of purine metabolism in a xanthinuric female. J Clin Invest (1968) 0.86
Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Biochem Biophys Res Commun (1999) 0.86
Cardiac glycosides in partly submerged shoots of Digitalis lanata. Planta Med (1993) 0.86
Hepatic perfusion with FUdR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver. Cancer Invest (1989) 0.86
Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos (1986) 0.86
Extraction and analytic procedures for cytosine arabinoside and 1-beta-D-arabinofuranosyluracil and their 5'-mono-, di-, and tri-phosphates. Cancer Treat Rep (1977) 0.85
13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst (1993) 0.85
Stability of refrigerated and frozen solutions of doxorubicin hydrochloride. Am J Hosp Pharm (1979) 0.84
Tracking issue attention: specifying the dynamics of the public agenda. Public Opin Q (2001) 0.84
Colitis and docetaxel-based chemotherapy. Lancet (2000) 0.84
Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. Invest New Drugs (1989) 0.83
Homoharringtonine: a phase I evaluation. Invest New Drugs (1985) 0.83
Biochemical, pharmacological, and phase I clinical evaluation of pseudoisocytidine. Cancer Res (1980) 0.83
Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol (1995) 0.83
Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion. Cancer Res (1981) 0.83
Phase I trial of vinzolidine. Cancer Treat Rep (1984) 0.82
Chemotherapy of gastrointestinal cancer. Cancer (1972) 0.82
Enzymatic degradation of cichoric acid in Echinacea purpurea preparations. J Nat Prod (2000) 0.82
Studies on drug resistance. I. Distribution of l-beta-D-arabinofuranosylcytosine, cytidine and deoxycytidine in mice bearing ara-C-sensitive and-resistant P815 neoplasms. Biochem Pharmacol (1969) 0.82
Phase I study of pentamethylmelamine. Cancer Treat Rep (1980) 0.82
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol (1987) 0.81
Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer (1983) 0.81
In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? Leukemia (2001) 0.81
Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone. Cancer Res (1987) 0.81
Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs. Cancer Res (1985) 0.81
The teratogenic effect of 1-beta-D-arabinofuranosylcytosine in the rat. Protection by deoxycytidine. Biochem Pharmacol (1968) 0.81
Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br J Cancer (2001) 0.81
Clinical pharmacology of trimetrexate. Clin Pharmacol Ther (1987) 0.81
Chemotherapy of germ cell tumors of the testis. I. Induction of remissions with vinblastine, actinomycin D, and bleomycin. Cancer (1976) 0.81
Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs (1991) 0.80
Analogs of 1-beta-D-arabinofuranosylcytosine. Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies. Biochem Pharmacol (1967) 0.80
Methionine dependency of malignant tumors. J Natl Cancer Inst (1991) 0.80
Effect of very high-dose thymidine infusions on leukemia and lymphoma patients. Cancer Res (1984) 0.80
Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer (1977) 0.79
IMP: and AMP:pyrophosphate phosphoribosyltransferase in leukemic and normal human leukocytes. Proc Soc Exp Biol Med (1971) 0.79
Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days. Cancer Res (1985) 0.79
Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP; NSC-107392), with special reference to its iron-chelating properties. Cancer Chemother Rep (1974) 0.79
Effect of hydroxylamine (NSC-26250) and related compounds on growth of transplanted animal tumors. Cancer Res (1966) 0.79
The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma. Eur J Cancer (1995) 0.79
Residual mediastinal mass after treatment of Hodgkin's disease: a decision analysis. Med Hypotheses (1992) 0.79
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs (1998) 0.79
Phase I study of high-dose etoposide phosphate in man. Bone Marrow Transplant (1996) 0.78
Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine. Cancer Res (1981) 0.78
Combination chemotherapy with cis-diamminedichloroplatinum and vinblastine in advanced non-small cell lung cancer. J Clin Oncol (1983) 0.78
Inhibition of uric acid biosynthesis in the chick embryo and chicken by a xanthine oxidase inhibitor, 4-hydroxypyrazolo(3,4d)pyrimidine. J Pharmacol Exp Ther (1965) 0.78
Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma. Cancer Treat Rep (1980) 0.78
Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Clin Pharmacol Ther (1990) 0.78
Studies on drug resistance. II. Kinase patterns in P815 neoplasms sensitive and resistant to 1-beta-D-arabinofuranosylcytosine. Biochem Pharmacol (1970) 0.78
Phase I trial of FK973: description of a delayed vascular leak syndrome. Invest New Drugs (1991) 0.78
Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells. Biochem Pharmacol (1999) 0.78
A clinical study of the natural history of lymphosarcoma and reticulum cell sarcoma. Eur J Cancer (1974) 0.78